Over 100 Republican Lawmakers Back Supreme Court Push to Reimpose Abortion Pill Restrictions as Access Hangs in the Balance

The Supreme Court is weighing whether to let stand a federal appeals court order that would end mail-order and telehealth access to mifepristone — the drug used in roughly two-thirds of all U.S. abortions — after more than 100 Republican lawmakers filed an amicus brief urging the justices to uphold the restriction [1][2]. The case has created a week-by-week legal cliffhanger, with Justice Samuel Alito issuing a temporary administrative stay on May 4, 2026, that expires May 11, preserving the status quo while the Court decides whether to block the Fifth Circuit's order for a longer period [3][4].

The dispute, Louisiana v. FDA, represents the second attempt in two years to roll back the FDA's 2023 decision to allow mifepristone to be prescribed via telehealth and shipped through the mail. The first attempt failed unanimously at the Supreme Court in June 2024, when all nine justices ruled that the anti-abortion doctors and organizations challenging the rules lacked standing to sue [5]. This time, the challengers believe they have found a new legal path — one routed through a state government's claim of direct financial harm.

The Amicus Brief: Who Signed and What They Argue

The Republican amicus brief is led by Sen. Bill Cassidy of Louisiana, who chairs the Senate Health, Education, Labor and Pensions Committee; Rep. Chris Smith of New Jersey; Senate Majority Leader John Thune of South Dakota; and House Speaker Mike Johnson of Louisiana [1]. More than 100 additional Republican lawmakers from both chambers joined.

The brief advances three principal arguments. First, it contends that the FDA's 2023 changes to mifepristone's Risk Evaluation and Mitigation Strategy (REMS) — which eliminated mandatory in-person dispensing and permitted retail pharmacy distribution — violated the Administrative Procedure Act by proceeding without adequate procedural justification [6]. Second, it invokes the Comstock Act, an 1873 statute that prohibits mailing any substance "designed, adapted, or intended for producing abortion," arguing the law categorically bars mailing mifepristone regardless of FDA authorization [7][8]. Third, it raises safety and coercion concerns, claiming that removing in-person oversight has enabled cases in which women were forced or tricked into taking abortion pills [1].

Sen. Cassidy stated: "Chemical abortion drugs kill innocent children and put mothers' lives at risk. Safeguards protecting against coercion ... must be reinstated immediately" [1]. Senate Majority Leader Thune added: "There are legitimate concerns about these drugs putting women and girls at significant risk" [1].

The Standing Question: What Changed Since 2024

The Supreme Court's unanimous 2024 decision in FDA v. Alliance for Hippocratic Medicine established that anti-abortion doctors lacked standing because they do not prescribe or use mifepristone and could not demonstrate a concrete personal injury from the FDA's regulatory changes [5]. Federal conscience laws, Justice Brett Kavanaugh wrote for the Court, already protect doctors from being compelled to perform abortions against their beliefs [5].

Louisiana's lawsuit attempts to overcome that ruling by asserting a different kind of injury: direct financial harm to the state. The state identifies approximately $92,000 in Medicaid expenditures from two women who required emergency care in 2025 after taking mifepristone received by mail [6][9]. Louisiana also argues that mail-delivered pills undermine its ability to enforce its own abortion ban [10].

Danco Laboratories, one of two mifepristone manufacturers that intervened to defend the FDA rules, contends Louisiana's Medicaid-cost theory is simply a "more attenuated version" of the standing arguments the Supreme Court already rejected [9]. If the Court accepts Louisiana's reasoning, Danco argues, any state could challenge any federal policy that generates downstream healthcare costs [9].

The Fifth Circuit, however, found Louisiana's standing sufficient. A three-judge panel ruled on May 1, 2026, that Louisiana demonstrated concrete injury traceable to the FDA's 2023 REMS changes [6][10].

Mifepristone's Safety Record: What the Data Shows

Mifepristone was approved by the FDA in 2000 and has been used by more than 7.5 million women in the United States [11]. The FDA's most recent post-marketing adverse events summary, covering data through December 31, 2024, reports 36 deaths associated with the drug over its entire 24-year history — a mortality rate of roughly 0.27 to 0.48 deaths per 100,000 uses [12][13]. Of those 36 deaths, 13 were attributed to sepsis caused by Clostridium bacterial infections [12].

Researchers at the University of California, San Francisco's ANSIRH program have concluded that mifepristone's serious adverse event rate is lower than that of common over-the-counter medications including penicillin, ibuprofen, and acetaminophen (Tylenol) [11][14]. A 2026 Johns Hopkins study found that FDA regulation of mifepristone from 2011 to 2023 was "shaped by evidence and caution," with the agency generally following its staff scientists' recommendations [15].

The Republican brief claims that "more than one in ten women experience complications including infection or hemorrhaging" [1]. Independent pharmacologists and reproductive health researchers dispute this figure, noting that the FDA's own data characterizes serious adverse events as "extremely rare" and that the 2016 elimination of non-death adverse event reporting requirements makes comprehensive tracking difficult [11][12].

Three studies published by the Charlotte Lozier Institute — the research arm of Susan B. Anthony Pro-Life America — that questioned mifepristone's safety record were retracted by the academic publisher Sage Journals between 2019 and 2022 [16]. Dr. Christina Francis, who has represented herself as president of the Alliance for Hippocratic Medicine (the lead plaintiff in the 2024 case), is an associate scholar at the Charlotte Lozier Institute [16]. The Alliance Defending Freedom, which litigated the 2024 case, donated more than $27,000 to the Charlotte Lozier Institute and $25,000 to AAPLOG (the American Association of Pro-Life Obstetricians and Gynecologists) in 2021 [16].

Source: Guttmacher Institute

Data as of Mar 1, 2026CSV

The Coercion Argument: Cases and Counter-Evidence

The amicus brief cites several cases to support its coercion claim. One involves Rosalie Markezich, whose boyfriend allegedly obtained mifepristone from a California doctor and forced her to take it [1]. Another describes a Louisiana mother who allegedly obtained abortion pills online for her teenage daughter, resulting in a medical emergency [1]. A third involves a man accused of administering the drug to a pregnant woman without her knowledge [1].

These cases are presented as evidence that mail-order access to mifepristone enables abuse. However, non-consensual administration of any drug is already a crime under existing state and federal law — a fact that critics argue undermines the case for additional regulatory restrictions [17].

The Guttmacher Institute, a reproductive health research organization, published an analysis in March 2026 characterizing the coercion framing as a "distortion" of what the research literature actually shows [17]. A 2018 systematic review of peer-reviewed studies on reproductive coercion found that the evidence "does not support the assertion that women are frequently coerced into abortions, but rather, that they are more often coerced into continuing a pregnancy" [17]. The National Domestic Violence Hotline reported that calls involving reproductive coercion nearly doubled in the first year after the Dobbs decision, with research documenting over 9,000 additional intimate partner violence incidents among women of reproductive age following state abortion bans [17].

Supporters of the coercion argument respond that these broader statistics do not negate the specific cases in which mail-ordered pills were misused, and that in-person dispensing requirements would create an additional safeguard against such misuse [1][10].

Who Would Lose Access — and Where

If the Supreme Court allows the Fifth Circuit ruling to take effect, mifepristone would revert to in-person-only dispensing nationwide. The impact would extend far beyond states with abortion bans.

According to Guttmacher Institute data, telehealth-provided abortions accounted for 24% of all U.S. abortions in 2025, up from just 4% in 2020 [18]. That translates to roughly 270,000 patients annually who obtained care through online clinics [18]. Medication abortion overall — including both in-person and telehealth prescriptions — accounted for 65% of all abortions in 2023 [19].

Source: Guttmacher Institute

Data as of Apr 1, 2026CSV

The burden of losing telehealth access would fall disproportionately on rural populations, low-income patients, and people with disabilities [20]. In states with existing abortion bans, average travel time to a clinic has already quadrupled — from under three hours to more than 11 hours — since the Dobbs decision [20]. Reproductive health advocates argue that an in-person dispensing requirement would compound those barriers even in states where abortion remains legal, because many patients in rural areas lack nearby providers [3][20].

Some providers have indicated they might shift to misoprostol-only regimens if mifepristone access through mail is cut off. Misoprostol alone is approximately 80–85% effective for early abortion compared to the 95–99% efficacy rate of the mifepristone-misoprostol combination [6].

The Trump Administration's Silence

One of the most unusual aspects of the case is the Trump administration's posture. The Department of Justice, which represents the FDA as a defendant in the lawsuit, did not file a brief defending the agency's 2023 rules by the May 7 deadline [21][3].

"It's wild that DOJ is taking no position on whether a federal regulation should or should not be blocked for the duration of this case," said Steve Vladeck, a Georgetown University Law Center professor [3]. The administration has raised procedural objections to Louisiana's lawsuit but has stopped short of defending mifepristone access on the merits [21].

This silence places the burden of defending the FDA's regulatory authority on the drug manufacturers themselves — Danco Laboratories and GenBioPro — who filed emergency applications with the Supreme Court on May 2 [4][9]. A group of 250 Democratic lawmakers filed their own amicus brief urging the Court to block the Fifth Circuit order [22], while nearly two dozen state attorneys general from states where abortion remains legal argued the ruling improperly subordinates their policy choices to the preferences of restriction-favoring states [3].

Former FDA leaders submitted a separate brief arguing that the Fifth Circuit's decision "would upend FDA's gold-standard, science-based drug approval system" [3].

The Comstock Act: A 19th-Century Law at the Center

Louisiana's invocation of the Comstock Act raises questions that extend well beyond mifepristone. The 1873 statute, originally part of a broader anti-obscenity campaign, prohibits the mailing of any article or substance "designed, adapted, or intended for producing abortion" [7][8].

In December 2022, the Department of Justice's Office of Legal Counsel concluded that the Comstock Act does not prohibit mailing abortion medications unless the sender intends them to be used unlawfully [7]. Louisiana's lawsuit argues for a broader reading: that the statute categorically prohibits mailing mifepristone regardless of the legality of abortion in the destination state [8].

The Fifth Circuit did not reach the Comstock Act question in its May 1 ruling, deciding the case on APA grounds instead [6]. Whether the Supreme Court addresses the Comstock argument could determine whether the case's impact remains limited to FDA regulatory procedure or expands into a broader confrontation over mail-order pharmaceutical distribution [7][8].

Timeline and What Comes Next

The immediate question is whether the Supreme Court will extend Justice Alito's administrative stay past May 11 [4]. If the Court declines to block the Fifth Circuit's order, in-person dispensing requirements would take effect nationwide — though the underlying case would continue through full litigation at the district and appellate levels.

If the Court grants a longer stay, current telehealth and mail access would remain in place while the case proceeds. Full briefing at the Supreme Court, if the justices take the case on the merits, would likely conclude by fall 2026, with oral argument possible in the October 2026 term and a decision expected by June 2027 [4][6].

The political calendar adds another dimension. Sen. Cassidy faces a Republican primary on May 16 — five days after the stay expires — and has publicly called for "expedited FDA review" of mifepristone as part of his campaign [23]. Susan B. Anthony Pro-Life America has endorsed him in that race [23]. Nationally, the 2026 midterm elections in November will take place against the backdrop of whatever the Court decides, and abortion policy has proven to be a powerful motivator for voter turnout since the Dobbs decision [21][23].

The Funding Web

The organizations generating the research and testimony cited in anti-mifepristone legal challenges share overlapping funding and personnel. The Charlotte Lozier Institute, which produced studies questioning mifepristone's safety (three of which were later retracted), is the research arm of Susan B. Anthony Pro-Life America [16]. The Alliance for Hippocratic Medicine, the lead plaintiff in the 2024 case, was registered as a nonprofit just months before filing suit, and its principal officer is the recently retired CEO of AAPLOG [16]. Alliance Defending Freedom, which litigated both the 2024 case and supports the current Louisiana challenge, has donated to both organizations [16].

On the other side, Danco Laboratories — the manufacturer of Mifeprex, the branded mifepristone product — is a private, single-product company that does not disclose its investors, though it has stated they include "wealthy individuals and foundations that supported abortion rights" [24]. The company was deliberately structured to be resistant to anti-abortion boycotts [24]. GenBioPro, which manufactures the generic version, has similarly intervened in the litigation alongside Danco [4].

Mainstream medical and reproductive health organizations that have filed briefs supporting mifepristone access — including the American College of Obstetricians and Gynecologists, the American Medical Association, and the Guttmacher Institute — receive funding from a range of philanthropic foundations, government grants, and membership dues, though none are single-issue entities in the way that anti-abortion organizations are [17][15].

What the Court's Decision Could Mean

The range of possible outcomes spans from narrow procedural resolution to broad regulatory disruption.

At the narrow end, the Court could dismiss the case on standing grounds, as it did in 2024, finding Louisiana's Medicaid-cost theory insufficiently concrete [5][9]. At the broad end, it could affirm the Fifth Circuit and uphold both the APA challenge and the Comstock Act argument — a ruling that could affect not just mifepristone but the mailing of any FDA-approved medication that opponents characterize as abortion-related [7][8].

A middle path might see the Court grant a stay while directing the lower courts to more thoroughly examine the standing and merits questions, effectively maintaining current access for a year or more while litigation continues [4].

Whatever the outcome, the case has already exposed a fracture in the federal government's approach to drug regulation. The FDA approved mifepristone's expanded access based on decades of safety data. The DOJ has declined to defend that decision. And more than 100 elected lawmakers are asking the Court to override the agency's scientific judgment based on a handful of criminal cases that existing law already addresses.

The May 11 deadline will determine whether the status quo holds or collapses — and whether the roughly 270,000 patients who obtain abortion care via telehealth each year will need to find another way.